Registered outcomes11

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

1 to 11 of 11

List	Outcome	Time frame	Description
Primary	Incidence of Adverse Events	From the time of cell infusion up to 12 months after NCR201 transplantation	To evaluate the safety and tolerability of stereotactic intracerebral injection of NCR201 by assessing the type, frequency, and severity of adverse events (AEs) and serious adverse events (SAEs).
Primary	Maximum Tolerated Dose (MTD) of NCR201	Within 12 months after NCR201 transplantation	Change from baseline in UPDRS Part III motor score to evaluate motor function improvement following NCR201 cell injection.
Secondary	Change in Unified Parkinson's Disease Rating Scale (UPDRS) Part III Score	Baseline, 3 months, 6 months and 12 months after NCR201 transplantation	Change from baseline in UPDRS Part III motor score to evaluate motor function improvement following NCR201 cell injection.
Secondary	Survival and engraftment of grafted cells assessed by brain PET/MRI imaging	Baseline, 6 months and 12 months after NCR201 transplantation	Brain PET and MRI imaging to evaluate the survival, location and engraftment of transplanted NCR201 dopaminergic progenitor cells in the putamen.
Secondary	Change in UPDRS Part II Activities of Daily Living Score	Baseline, 3 months, 6 months and 12 months after NCR201 transplantation	Change from baseline in UPDRS Part II score to assess activities of daily living in Parkinson's subjects after NCR201 treatment.
Secondary	Change in levodopa equivalent daily dose (LEDD)	Baseline, 3 months, 6 months and 12 months after NCR201 transplantation	Change from baseline in levodopa equivalent daily dose (LEDD) to assess reduction of anti-parkinson medication requirement.
Secondary	Change in UPDRS Part I Non-motor Experiences of Daily Living Score	Baseline, 3 months, 6 months and 12 months after NCR201 transplantation	Change from baseline in UPDRS Part I score to evaluate non-motor symptoms in Parkinson's patients receiving NCR201.
Secondary	Incidence of anti-NCR201 alloantibody formation	Baseline, 1 month, 3 months, 6 months and 12 months after NCR201 transplantation	Detection of anti-donor alloantibodies in peripheral blood to assess immune response against transplanted NCR201 cells.
Secondary	Change in Parkinson's Disease Questionnaire (PDQ-39) quality of life score	Baseline, 6 months and 12 months after NCR201 transplantation	Change from baseline in PDQ-39 total score to evaluate health-related quality of life after NCR201 cell transplantation.
Secondary	Change in dyskinesia rating scale score	Baseline, 3 months, 6 months and 12 months after NCR201 transplantation	Change from baseline in dyskinesia rating scale to assess the severity of levodopa-induced dyskinesia.
Secondary	Duration of on-time without troublesome dyskinesia	Baseline, 3 months, 6 months and 12 months after NCR201 transplantation	Assessment of daily "on" time without troublesome dyskinesia based on patient diaries after NCR201 treatment.

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT07896187/registered

API reference For AI assistants